Key Points
- CFO Scott Blumberg sold 36,000 shares on Dec. 22 at an average price of $21 for a $756,000 transaction, reducing his holding by 23.25% to 118,842 shares (about $2.5M).
- CeriBell remains unprofitable: it reported EPS of ($0.37) last quarter (beating estimates of ($0.43)) with $22.59M revenue, but analysts forecast about -2.46 EPS for the year and the company shows negative margins and ROE.
- Shares trade near $21.39 with a market cap of ~$793.6M and a 52‑week range of $10.01–$26.83; analysts' consensus is a Moderate Buy with a $24.67 target (majority Buy ratings, one Sell).
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) CFO Scott Blumberg sold 36,000 shares of the business's stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $21.00, for a total transaction of $756,000.00. Following the completion of the sale, the chief financial officer owned 118,842 shares of the company's stock, valued at approximately $2,495,682. The trade was a 23.25% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.
CeriBell Price Performance
Shares of NASDAQ:CBLL opened at $21.39 on Tuesday. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12. The stock has a market cap of $793.57 million, a PE ratio of -14.17 and a beta of 1.30. The company's fifty day moving average is $16.31 and its 200 day moving average is $14.80. CeriBell, Inc. has a 52 week low of $10.01 and a 52 week high of $26.83.
CeriBell (NASDAQ:CBLL - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.43) by $0.06. The firm had revenue of $22.59 million for the quarter, compared to analysts' expectations of $21.78 million. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%. Research analysts anticipate that CeriBell, Inc. will post -2.46 earnings per share for the current year.
Institutional Trading of CeriBell
Large investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in CeriBell during the 3rd quarter valued at $33,000. Tower Research Capital LLC TRC increased its position in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company's stock valued at $43,000 after buying an additional 1,801 shares during the period. Ameritas Investment Partners Inc. raised its stake in CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company's stock worth $48,000 after buying an additional 1,256 shares in the last quarter. Police & Firemen s Retirement System of New Jersey lifted its holdings in CeriBell by 161.0% in the second quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company's stock worth $106,000 after buying an additional 3,502 shares during the period. Finally, Sherbrooke Park Advisers LLC bought a new stake in CeriBell during the 3rd quarter valued at approximately $135,000.
Analyst Upgrades and Downgrades
CBLL has been the subject of several recent research reports. Weiss Ratings reiterated a "sell (e+)" rating on shares of CeriBell in a research report on Wednesday, October 8th. TD Cowen decreased their target price on shares of CeriBell from $36.00 to $20.00 and set a "buy" rating on the stock in a research note on Wednesday, November 5th. BTIG Research reissued a "buy" rating and set a $30.00 price target on shares of CeriBell in a research report on Monday, December 15th. Cowen reissued a "buy" rating on shares of CeriBell in a report on Tuesday, December 9th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of CeriBell from $21.00 to $17.00 and set an "overweight" rating for the company in a research note on Wednesday, November 5th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $24.67.
Read Our Latest Report on CeriBell
About CeriBell
(
Get Free Report)
CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell's solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.
The company's product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
